Don B. Axworthy

778 total citations
14 papers, 634 citations indexed

About

Don B. Axworthy is a scholar working on Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Don B. Axworthy has authored 14 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Pathology and Forensic Medicine and 3 papers in Molecular Biology. Recurrent topics in Don B. Axworthy's work include Radiopharmaceutical Chemistry and Applications (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Lymphoma Diagnosis and Treatment (7 papers). Don B. Axworthy is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Lymphoma Diagnosis and Treatment (7 papers). Don B. Axworthy collaborates with scholars based in United States, Canada and United Kingdom. Don B. Axworthy's co-authors include Oliver W. Press, D. Scott Wilbur, Hazel B. Breitz, Don K. Hamlin, Damon L. Meyer, Paul L. Weiden, Louis Theodore, Robert W. Mallett, Eric Kin Cheong Yau and Diane Stone and has published in prestigious journals such as Blood, Analytical Biochemistry and Bioconjugate Chemistry.

In The Last Decade

Don B. Axworthy

14 papers receiving 622 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Don B. Axworthy United States	11	524	204	134	85	83	14	634
Don K. Hamlin United States	8	322 0.6×	122 0.6×	69 0.5×	57 0.7×	65 0.8×	12	402
James Sanderson United States	10	389 0.7×	61 0.3×	136 1.0×	55 0.6×	167 2.0×	10	528
SJ Knox United States	12	387 0.7×	138 0.7×	142 1.1×	117 1.4×	134 1.6×	21	586
Fu Su China	7	281 0.5×	74 0.4×	82 0.6×	32 0.4×	95 1.1×	8	390
R M Sharkey United States	18	695 1.3×	124 0.6×	216 1.6×	130 1.5×	151 1.8×	21	818
Catherine Saï-Maurel France	14	323 0.6×	38 0.2×	126 0.9×	64 0.8×	84 1.0×	24	422
G. Rowlinson United Kingdom	7	285 0.5×	53 0.3×	122 0.9×	49 0.6×	94 1.1×	10	435
Sébastien Gouard France	18	450 0.9×	33 0.2×	259 1.9×	178 2.1×	159 1.9×	37	758
Paul Chinn United States	8	365 0.7×	244 1.2×	140 1.0×	89 1.0×	67 0.8×	11	532
J.C. Saccavini France	12	382 0.7×	54 0.3×	104 0.8×	72 0.8×	120 1.4×	25	493

Countries citing papers authored by Don B. Axworthy

Since Specialization

Citations

This map shows the geographic impact of Don B. Axworthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don B. Axworthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don B. Axworthy more than expected).

Fields of papers citing papers by Don B. Axworthy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don B. Axworthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don B. Axworthy. The network helps show where Don B. Axworthy may publish in the future.

Co-authorship network of co-authors of Don B. Axworthy

This figure shows the co-authorship network connecting the top 25 collaborators of Don B. Axworthy. A scholar is included among the top collaborators of Don B. Axworthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don B. Axworthy. Don B. Axworthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Cheal, Sarah M., Barney Yoo, Sarah Boughdad, et al.. (2013). Evaluation of Glycodendron and Synthetically Modified Dextran Clearing Agents for Multistep Targeting of Radioisotopes for Molecular Imaging and Radioimmunotherapy. Molecular Pharmaceutics. 11(2). 400–416. 9 indexed citations

Jia, Fang, Jeffrey N. Bryan, Cathy S. Cutler, et al.. (2011). Comparison of Pretargeted and Conventional CC49 Radioimmunotherapy Using ¹⁴⁹Pm, ¹⁶⁶Ho, and ¹⁷⁷Lu. Bioconjugate Chemistry. 22(12). 2444–2452. 22 indexed citations

Pantelias, Anastasia, John M. Pagel, Donald K. Hamlin, et al.. (2007). Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood. 109(11). 4980–4987. 29 indexed citations

Forero‐Torres, Andres, Sui Shen, Hazel B. Breitz, et al.. (2005). Pretargeted Radioimmunotherapy (RIT) with a Novel Anti-TAG-72 Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals. 20(4). 379–390. 20 indexed citations

Beaumier, Paul L., et al.. (2005). Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Nuclear Medicine and Biology. 32(7). 741–747. 48 indexed citations

Forero, Andres, Paul L. Weiden, Julie M. Vose, et al.. (2004). Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood. 104(1). 227–236. 117 indexed citations

Hamblett, Kevin J., Oliver W. Press, Damon L. Meyer, et al.. (2004). Role of Biotin-Binding Affinity in Streptavidin-Based Pretargeted Radioimmunotherapy of Lymphoma. Bioconjugate Chemistry. 16(1). 131–138. 27 indexed citations

Graves, Scott S., Yukang Lin, James Sanderson, et al.. (2003). Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.. PubMed. 9(10 Pt 1). 3712–21. 44 indexed citations

Hamlin, Don K., John M. Pagel, D. Scott Wilbur, et al.. (2003). Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.. PubMed. 44(3). 437–45. 57 indexed citations

10.

Hylarides, Mark D., Don B. Axworthy, & Alan R. Fritzberg. (2001). Preparation of ²¹³bi‐dota‐biotin in high specific activity for pretargeted alpha radiotherapy of cancer. Journal of Labelled Compounds and Radiopharmaceuticals. 44(S1). 1 indexed citations

11.

Press, Oliver W., Don K. Hamlin, D. Scott Wilbur, et al.. (2001). A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 98(8). 2535–2543. 121 indexed citations

12.

Wilbert, Sibylle, et al.. (2000). Quantitative Analysis of a Synthetic Peptide, NR58-3.14.3, in Serum by LC-MS with Inclusion of a Diastereomer as Internal Standard. Analytical Biochemistry. 278(1). 14–21. 21 indexed citations

13.

Weiden, Paul L., Hazel B. Breitz, Oliver W. Press, et al.. (2000). Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results. Cancer Biotherapy and Radiopharmaceuticals. 15(1). 15–29. 110 indexed citations

14.

Graves, Scott S., Diane Stone, Don B. Axworthy, et al.. (1999). Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody.. PubMed. 5(4). 899–908. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact